Chinese digital health platform offering online pharmacy, healthcare services, telemedicine, and health management services.
Profile & Fundamentals
JD Health: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
JD Health Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions. In addition, it provides online marketing services to advertisers; and online shopping and hospital services. Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products. Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services. The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies. JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
Company profile record
Jd Health International Inc
Common Stock · Health Care · Health Care Facilities
Company
- Company / asset
- Jd Health International Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Facilities
- HQ
- 🇨🇳 China
- Head office
- Jingdong Headquarters, Beijing, China, 101111
Leadership & scale
- Chief executive
- Mr. Cao Dong
- CEO year born
- 1977
- Full-time employees
- 6K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- HKD 112.6B
- P/E
- 9.4x
- Revenue (Q2 26)
- CNY 40.3B
- Profit (Q2 26)
- CNY 3.4B
- Dividend Yield
- --
- Revenue (FY 25)
- CNY 73.4B
- Shares in public float
- 1B
- Insider ownership
- 68.2%
Reporting & identifiers
- Symbol
- 6618.HKEX
- Listing
- 🇭🇰 Hong Kong | Dividend Tax: 0%
- Ticker Currency
- HKD
- Income Statement Currency
- CNY
- Balance Sheet Currency
- CNY
- Cash Flow Currency
- CNY
- EPS Currency
- CNY
- Contract Type
- SPOT
- ISIN
- KYG5074A1004
- Asset ID
- equity_21381989-d6f7-5f5e-a316-4ab9600ebdb7
Ownership
Shares Outstanding
Latest: 3.2B | Max: 3.2B | Min: 2.3B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
31.51%
1.0B latest reported shares
Insider Ownership
68.20%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 3,127,082,100 |
| 2018-01-01 | 3,127,082,100 |
| 2019-01-01 | 2,638,167,900 |
| 2020-01-01 | 2,267,793,700 |
| 2021-01-01 | 3,098,101,000 |
| 2022-01-01 | 3,149,005,000 |
| 2023-01-01 | 3,165,458,000 |
| 2024-01-01 | 3,164,855,000 |
| 2025-01-01 | 3,202,719,000 |
| 2026-01-01 | 3,204,362,000 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
JD Health's financial performance highlights a company steadily increasing its underlying business profits despite wider economic challenges in China. In the first half of 2026, revenue grew 15.9% to RMB 40.9 billion, while net profit rose 32.4% to RMB 3.44 billion, driven by surging repeat orders for essential chronic disease medications. However, headlines slightly overstate the underlying operating momentum. When excluding non-operating items and shrinking interest income on treasury deposits, adjusted operating profit grew by 8.5%. Cash collection remains exceptionally healthy, converting top-line sales into substantial free cash flow due to favorable payment terms with suppliers.
JD Health's financial performance highlights a company steadily increasing its underlying business profits despite wider economic challenges in China. In the first half of 2026, revenue grew 15.9% to RMB 40.9 billion, while net profit rose 32.4% to RMB 3.44 billion, driven by surging repeat orders for essential chronic disease medications. However, headlines slightly overstate the underlying operating momentum. When excluding non-operating items and shrinking interest income on treasury deposits, adjusted operating profit grew by 8.5%. Cash collection remains exceptionally healthy, converting top-line sales into substantial free cash flow due to favorable payment terms with suppliers.
Revenue, Net Income, and Free Cash Flow
Latest: CNY 73.4B | Max: CNY 73.4B | Min: CNY -17.2B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 18x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability margins have expanded steadily as the business shifts toward higher-value products and automated services. Consolidated gross margin reached a record 26.1% in the first half of 2026, rising from 24.8% in 2025, supported by specialized prescription drugs and high-margin third-party marketplace commissions. Operating efficiency has improved for nine consecutive quarters, bringing non-IFRS operating margins to 8.5%. While government price adjustments on generic medications create ongoing pricing headwinds, automated warehouse sorting and direct supplier relationships have successfully lowered unit fulfillment costs, preserving reliable underlying profitability across the platform.
Profitability margins have expanded steadily as the business shifts toward higher-value products and automated services. Consolidated gross margin reached a record 26.1% in the first half of 2026, rising from 24.8% in 2025, supported by specialized prescription drugs and high-margin third-party marketplace commissions. Operating efficiency has improved for nine consecutive quarters, bringing non-IFRS operating margins to 8.5%. While government price adjustments on generic medications create ongoing pricing headwinds, automated warehouse sorting and direct supplier relationships have successfully lowered unit fulfillment costs, preserving reliable underlying profitability across the platform.
Profitability Margins
Latest: 24.8% | Max: 25.9% | Min: -88.9%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
24.8%
Gross profit / revenue
Operating Margin
5.2%
Operating income / revenue
Net Margin
7.3%
Net income / revenue
FCF Margin
13.3%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2017-12-31 | 853,015,053.76 | 27,424,577.57 | 4,223,195.08 |
| 2018-12-31 | 1,187,362,936.05 | 31,239,389.53 | 26,861,918.6 |
| 2019-12-31 | 1,557,778,735.63 | -139,627,155.17 | 58,086,781.61 |
| 2020-12-31 | 2,968,233,996.94 | -2,639,259,264.93 | 564,129,402.76 |
| 2021-12-31 | 4,824,255,817.61 | -168,790,408.81 | 460,457,389.94 |
| 2022-12-31 | 6,773,355,072.46 | 55,087,681.16 | 849,998,405.8 |
| 2023-12-31 | 6,854,025,736.24 | 274,243,405.89 | 638,795,070.42 |
| 2024-12-31 | 7,485,184,169.88 | 535,629,858.43 | 551,610,296.01 |
| 2025-12-31 | 10,506,650,500.72 | 769,013,590.84 | 1,395,239,546.35 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 17.65 | Trailing four quarters |
| 2024-12-31 | 13.89 | Trailing four quarters |
| 2022-12-31 | 522.23 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2017-12-31 | 24.86 | 4.62 | 3.22 | 0.5 |
| 2018-12-31 | 24.23 | 3.76 | 2.63 | 2.26 |
| 2019-12-31 | 25.94 | 3.98 | -8.96 | 3.73 |
| 2020-12-31 | 25.37 | 1.81 | -88.92 | 19.01 |
| 2021-12-31 | 23.46 | -4.58 | -3.5 | 9.54 |
| 2022-12-31 | 21.16 | -0.31 | 0.81 | 12.55 |
| 2023-12-31 | 22.17 | 1.31 | 4 | 9.32 |
| 2024-12-31 | 22.88 | 2 | 7.16 | 7.37 |
| 2025-12-31 | 24.78 | 5.17 | 7.32 | 13.28 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-10.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.